: iStockAnalyst.com Symbols Feed

Emergent BioSolutions Hits Investors Business Daily

Mon, 01 Dec 2008 18:53:00 GMT

Investors Business Daily has an article out on Emergent BioSolutions (EBS) that could read straight out of the blog - namely, it has a customer whose pockets are endless and a long sight line on revenue (a rarity in this market) - remember, we have 2 names who rely on government and ironically both are up today in the casino (AVAV being the other). The one thing missing from the story is the recent shelf filing (Nov 13: Emergent BioSolutions Files Shelf Offering) which has the potential to cause some serious dilution - the market has dismissed this completely; after a quick fall on the news, the stock has skyrocketed right back up. Nothing really new for blog readers but thought I'd put the story up due to the positive notice of this small cap[More...]

Trial: HIV vaccine 31 percent effective

Thu, 24 Sep 2009 17:41:00 GMT

Trial: HIV vaccine 31 percent effective[More...]

OXiGENE to Acquire VaxGen in a Stock-for-Stock Merger

Thu, 15 Oct 2009 10:48:00 GMT

Acquisition to Add Approximately $33 Million in Cash
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, and VaxGen, Inc. (OTCBB:VXGN), a biopharmaceutical company, announced today that they have entered into a definitive merger agreement pursuant to which OXiGENE will acquire VaxGen in exchange for common stock of OXiGENE.
Upon closing of the transaction, VaxGen will become a wholly-owned subsidiary of OXiGENE, and VaxGen stockholders will become stockholders of OXiGENE.

[More...]

The VaxGen Full Value Committee Nominates Five Highly Qualified Candidates to Replace Current VaxGen Board

Tue, 22 Sep 2009 19:50:00 GMT

The VaxGen Full Value Committee (Committee) today reported that, on September 17th, it delivered to VaxGen Inc. (OTCBB:VXGN) a solicitation notice for the nomination of five highly qualified director candidates to reconstitute the board of VaxGen at the upcoming 2009 annual meeting.
Members of the Committee, which currently consist of BA Value Investors LLC, a private investment firm founded by Steven N. Bronson, and ROI Capital Management, a registered investment advisor managed by Mark T. Boyer and Mitchell J. Soboleski, collectively own 13.7% of the outstanding common stock of VaxGen.
Explore ways to monetize VaxGen's value as a "public shell," including the utilization of the Company's substantial net operating losses; and

[More...]

VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment

Wed, 27 Aug 2008 21:40:00 GMT

VaxGen, Inc. , a biopharmaceutical company, today provided a financial and operational update since the filing of its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 14, 2008.[More...]

VaxGen Receives Repayment in Full of Bridge Loan to Raven biotechnologies

Thu, 17 Jul 2008 21:40:00 GMT

VaxGen, Inc. , a biopharmaceutical company, today announced that it has received repayment in full, including accrued interest, of the bridge loan it extended to Raven biotechnologies Inc. in connection with the proposed merger between the two companies. The proposed merger was terminated by mutual consent in March 2008. The total amount received from Raven in repayment was $6.27 million.[More...]

VaxGen Restructures Board of Directors - May 26 2008 10:31PM

Thu, 22 May 2008 23:33:00 GMT

Governance changes intended to support renewed strategic transaction effort[More...]

Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance - May 27 2008 12:53AM

Wed, 14 May 2008 22:13:00 GMT

VaxGen, Inc. , a biopharmaceutical company, today provided guidance on its expected monthly cash expenditures following the most recent restructuring undertaken on April 9, 2008. VaxGen expects that its average monthly cash expenditures going forward are unlikely to exceed $1 million, made up of the following categories:[More...]

VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc. - Jun 2 2008 2:18AM

Mon, 05 May 2008 03:57:00 GMT

VaxGen, Inc. , a biopharmaceutical company, announced today it has completed the sale of all assets and rights related to its recombinant protective antigen anthrax vaccine product candidate and related technology to Emergent BioSolutions, Inc. Under the terms of the transaction, Emergent BioSolutions paid VaxGen $2 million upon execution of the definitive agreement and may be obligated to pay up to an additional $8 million in milestone payments, plus specified percentages of future net sales.[More...]

VaxGen Restructures Following Termination of Proposed Merger

Wed, 09 Apr 2008 10:50:00 GMT

VaxGen, Inc. , a biopharmaceutical company, announced that the Company has initiated a restructuring to minimize expenses following the termination of the proposed merger between VaxGen and Raven biotechnologies, inc. VaxGen has moved to terminate the staff which it had retained in anticipation of the needs of the merged company. As a result, VaxGen will be terminating approximately 75% of its remaining staff of 22 persons, including Matthew Pfeffer, the Company's CFO and Senior Vice President of Finance and Administration.[More...]